Clinical benefit seen when investigational agent is combined with letrozole

The combination of the investigational agent PD 0332991 and letrozole significantly improved median progression-free survival in patients with advanced estrogen receptor-positive breast cancer, according to results from this phase II study. PD 0332991 is a novel oral selection inhibitor of cyclin-dependent kinase (CDK) 4/6 that prevents cellular DNA synthesis by blocking cell cycle progression. This research was presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. Read more here.